Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Allarity Therapeutics A/S
  6. Summary
    ALLR   DK0060732477

ALLARITY THERAPEUTICS A/S

(ALLR)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Stockholm
11/22/2021 11/23/2021 11/24/2021 11/25/2021 11/26/2021 Date
2.8(c) 2.6(c) 2.504(c) 2.41(c) 2.22(c) Last
17 291 834 9 368 814 7 688 885 15 461 559 9 087 108 Volume
-1.69% -7.14% -3.69% -3.75% -7.88% Change
More quotes
Estimated financial data (e)
Sales 2021 - - -
Net income 2021 -98,2 M -10,7 M -10,7 M
Net cash position 2021 27,2 M 2,97 M 2,97 M
P/E ratio 2021 -5,50x
Yield 2021 -
Sales 2022 - - -
Net income 2022 - - -
Net Debt 2022 - - -
P/E ratio 2022 -
Yield 2022 -
Capitalization 896 M 98,4 M 97,9 M
EV / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees 14
Free-Float 80,0%
More Financials
Company
Allarity Therapeutics A/S, formerly known as ONCOLOGY VENTURE A/S, is a Danmark-based company engaged in the development of anticancer medicines. The Company s current priority program focus is on the advancement of three precision medicine treatments: 2X-121, Dovitinib and Ixempra targeting the market for the treatment of ovarian cancer, breast cancer, and renal cell carcinoma. 
More about the company
All news about ALLARITY THERAPEUTICS A/S
11/24Allarity Therapeutics A/S Publishes Offer Document Offering to Acquire Company Shares i..
AQ
11/24Grant of New Warrants and Resolutions on Existing Warrants
AQ
11/23Allarity Therapeutics Publishes Interim Report for the Period January – September..
AQ
11/23Allarity Therapeutics A/S Reports Earnings Results for the Third Quarter and Nine Month..
CI
11/22Minutes of Extraordinary General Meeting held on 22 November 2021
AQ
11/11Allarity Therapeutics' Oral PARP Inhibitor, Stenoparib, Demonstrates Pre-clinical Antiv..
GL
11/11Allarity Therapeutics' Oral PARP Inhibitor, Stenoparib, Demonstrates Pre-clinical Antiv..
GL
11/11Allarity Therapeutics A/S Announces Positive Results from the Further Pre-Clinical Test..
CI
11/05Notice of the extraordinary general meeting of shareholders of allarity therapeutics a/..
AQ
11/05U.S. SEC Issues Order Declaring Allarity Therapeutics Inc.'s Form S-4 Registration Stat..
GL
11/05U.S. SEC Issues Order Declaring Allarity Therapeutics Inc.'s Form S-4 Registration Stat..
GL
09/24LONZA : To Manufacture Allarity Therapeutics' Kidney Cancer Candidate Dovitinib
MT
09/23ALLARITY THERAPEUTICS A/S : and Lonza Collaborate to Manufacture Dovitinib, a Renal Cell C..
AQ
09/16Allarity Therapeutics Presents Dovitinib Survival Data from DRP« Screened RCC Patients ..
GL
09/16Allarity Therapeutics A/S Presents Dovitinib Survival Data from DRP Screened RCC Patien..
CI
More news
News in other languages on ALLARITY THERAPEUTICS A/S
09/24Lonza va fabriquer le Dovitinib, le candidat d'Allarity Therapeutics pour le cancer du ..
09/23BOURSE ZURICH : les indices finissent nettement dans le vert
09/23AKTIEN SCHWEIZ SCHLUSS : SMI legt nach Zinsentscheiden klar zu
09/23BOURSE ZURICH : le SMI se rapproche des 12'000 points
09/23AKTIEN SCHWEIZ : Erholung hält an - SMI baut nach SNB-Entscheid Gewinne aus
More news
Chart ALLARITY THERAPEUTICS A/S
Duration : Period :
Allarity Therapeutics A/S Technical Analysis Chart | ALLR | DK0060732477 | MarketScreener
Technical analysis trends ALLARITY THERAPEUTICS A/S
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 0
Last Close Price 2,22 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Steve R. Carchedi Chief Executive Officer & Director
Jens Erik Knudsen Chief Financial Officer
Duncan Charles Mcnaught Moore Chairman
Steen Meier Knudsen Chief Science Officer
Thomas H. Jensen Chief Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
ALLARITY THERAPEUTICS A/S177.50%98
MODERNA, INC.215.53%133 648
LONZA GROUP AG29.85%59 443
IQVIA HOLDINGS INC.46.26%50 064
SEAGEN INC.-3.22%30 994
CELLTRION, INC.-40.39%24 431